<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745717</url>
  </required_header>
  <id_info>
    <org_study_id>Shanghai1st-48</org_study_id>
    <nct_id>NCT02745717</nct_id>
  </id_info>
  <brief_title>The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia</brief_title>
  <official_title>The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To evaluate if additional cord blood transfusion could accelerate the hematopoietic&#xD;
      reconstitution in severe aplastic anemia(SAA) patients receiving immunosuppressive therapy&#xD;
      (IST).&#xD;
&#xD;
      Study design: open-labed, prospective, multicenter, randomized control study Number of&#xD;
      subjects: 60 each group&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      IST group: ATG (Thymoglobuline®, Genzyme) 3.5mg/kg/d×5d plus oral cyclosporine A (CSA) Cord&#xD;
      blood transfusion group: In addition to the same dose and course of ATG and CSA , one unit of&#xD;
      cord blood having no more than 2 HLA-A, B or DRB1 mismatches is transfused 24h after last&#xD;
      dose of ATG administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients should be under 60 years old with confirmed SAA, without HLA matched&#xD;
      siblings and previous ATG treatment history. Patients will be excluded if they present any&#xD;
      fatal disease, including respiratory failure, heart failure, liver or kidney function failure&#xD;
      et al or severely allergic to biologic products.&#xD;
&#xD;
      To evaluate if additional cord blood transfusion could accelerate the hematopoietic&#xD;
      reconstitution in severe aplastic anemia(SAA) patients receiving IST therapy, 120 eligible&#xD;
      patients will be randomized to two groups, the IST group and the cord blood transfusion&#xD;
      group. Patients in the IST group receive standard IST which including ATG (Thymoglobuline®,&#xD;
      Genzyme) 3.5mg/kg/d×5d plus oral cyclosporine A（CSA ) started from 5mg/kg/d and adjusted to&#xD;
      maintain trough serum concentration of 200-300ng/ml. While patients in the cord blood&#xD;
      transfusion group receive the same dose and course of ATG and CSA as the control group and&#xD;
      one unit of cord blood having no more than 2 HLA-A, B and DRB1 mismatches is transfused 24h&#xD;
      after last dose of ATG administration.&#xD;
&#xD;
      The neutrophil recovery day is defined as the first day of 3 consecutive days during which&#xD;
      the absolute neutrophil count (ANC) is &gt;0.5×109/L, without G-CSF adminstration. Platelet&#xD;
      recovery day is deﬁned to have occurred on the ﬁrst of 7 consecutive days with a blood&#xD;
      platelet count (BPC) of &gt;20×109/L, without transfusion support. Response (CR, PR or NR) is&#xD;
      evaluated on 3, 4, 6,9, 12, 18 and 24months after treatment.&#xD;
&#xD;
      The primary end point is the neutrophil recovery day and second end points are response rate&#xD;
      (CR+PR), treatment related mortality, disease free survival and overall survival.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neutrophil recovery day</measure>
    <time_frame>5 days to 365 days</time_frame>
    <description>the first day of 3 consecutive days when the absolute neutrophil count (ANC) reaches 0.5×10^9/L, without G-CSF administration .&#xD;
The day of first dose of ATG administration is record as day 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>3 months to 24 months</time_frame>
    <description>overall response rate is the percentage of patients who acquire complete remission and partial remission according to the criteria of British Committee for Standards in Haematology (BCSH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24month</time_frame>
    <description>The length of time from the start of treatment for patients with SAA are still alive.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>3months, 24months</time_frame>
    <description>The death rate of patients because of treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>cord blood and IST group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IST group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days</description>
    <arm_group_label>IST group</arm_group_label>
    <arm_group_label>cord blood and IST group</arm_group_label>
    <other_name>Thymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cord blood</intervention_name>
    <description>transfusion of one unit of at least 4/6 HLA loci matched cord blood.</description>
    <arm_group_label>cord blood and IST group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Oral Product</intervention_name>
    <description>administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.</description>
    <arm_group_label>IST group</arm_group_label>
    <arm_group_label>cord blood and IST group</arm_group_label>
    <other_name>cyclosporine A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1．Diagnosis of AA confirmed by bone marrow aspirate and biopsy, myelodysplastic syndrome&#xD;
        and paroxysmal nocturnal hemoglobinuria were excluded. To confirm severe AA, the patient&#xD;
        must fulfill at least two of the criteria: i) ANC&lt;0.5×109/L,ii)PLT&lt;20×109/L and iii)&#xD;
        Ret&lt;20×109/L ,in addition, ANC&lt;0.5×109/L must be included.&#xD;
&#xD;
        2. Under 60 years old, male or female.&#xD;
&#xD;
        3. No HLA matched siblings.&#xD;
&#xD;
        4. No previous ATG treatment history.&#xD;
&#xD;
        5. Performance status score no more than 2 (ECOG criteria).&#xD;
&#xD;
        6．Adequate organ function as defined by the following criteria:ALT, AST and total serum&#xD;
        bilirubin &lt;2×ULN (upper limit of normal) Serum creatinine and BUN &lt;1.25×ULN.&#xD;
&#xD;
        7. Adequate cardiac function without acute myocardial infarction, arrhythmia or&#xD;
        atrioventricular block, heart failure, active rheumatic heart disease and cardiac&#xD;
        dilatation.&#xD;
&#xD;
        8．Signed and dated informed consent document indicating that the patient (or legally&#xD;
        acceptable representative) has been informed of all pertinent aspects of the trial prior to&#xD;
        enrollment.&#xD;
&#xD;
        9. Willingness and ability to comly with scheduled visits, treatment plans, laboratory&#xD;
        tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any condition inappropriate for HSCT.&#xD;
&#xD;
          2. Presence of any fatal disease, including respiratory failure, heart failure, liver or&#xD;
             kidney function failure et al.&#xD;
&#xD;
        3．Severely allergic to biologic products.&#xD;
&#xD;
        4．Pregnancy or breastfeeding.&#xD;
&#xD;
        5．Current treatment on another clinical trail.&#xD;
&#xD;
        6．Any other condition the investigator judged the patient inappropriate for entry into this&#xD;
        study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Wang, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieling Jiang, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>jiangjieling66@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Wan, M.D.,Ph. D.</last_name>
    <phone>86-21-63240090</phone>
    <phone_ext>3921</phone_ext>
    <email>wanliping924@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai general hospital, Shanghai Jiaotong university school of medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingpeng Wang, M.D., Ph.D.</last_name>
      <phone>86-21-63069298</phone>
      <email>sfph_edu2@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanhong Zhu, M.S</last_name>
      <phone>86-21-63240090</phone>
      <phone_ext>6213</phone_ext>
      <email>sfph_edu2@shumu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jieling Jiang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC; British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016 Jan;172(2):187-207. doi: 10.1111/bjh.13853. Epub 2015 Nov 16. Erratum in: Br J Haematol. 2016 Nov;175(3):546.</citation>
    <PMID>26568159</PMID>
  </reference>
  <reference>
    <citation>Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY, Tang BI, Tong J, Wang ZY. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant. 2012 Sep;47(9):1186-90. doi: 10.1038/bmt.2011.251. Epub 2012 Jan 16.</citation>
    <PMID>22246086</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chun Wang</investigator_full_name>
    <investigator_title>director, department of hematology</investigator_title>
  </responsible_party>
  <keyword>Severe aplastic anemia</keyword>
  <keyword>immunosuppressive therapy</keyword>
  <keyword>cord blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

